Pulse Biosciences/$PLSE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Ticker
$PLSE
Sector
Primary listing
Employees
75
Headquarters
Website
PLSE Metrics
BasicAdvanced
$977M
-
-$1.07
1.60
-
Price and volume
Market cap
$977M
Beta
1.6
52-week high
$25.00
52-week low
$13.77
Average daily volume
173K
Financial strength
Current ratio
12.047
Quick ratio
11.846
Long term debt to equity
6.495
Total debt to equity
7.891
Profitability
EBITDA (TTM)
-71.098
Management effectiveness
Return on assets (TTM)
-56.20%
Return on equity (TTM)
-103.50%
Valuation
Price to book
9.35
Price to tangible book (TTM)
9.69
Price to free cash flow (TTM)
-20.576
Free cash flow yield (TTM)
-4.86%
Free cash flow per share (TTM)
-0.706
Growth
Earnings per share change (TTM)
39.14%
3-year earnings per share growth (CAGR)
-19.06%
What the Analysts think about PLSE
Analyst ratings (Buy, Hold, Sell) for Pulse Biosciences stock.
Bulls say / Bears say
GAAP net loss increased to $19.2 million in Q2 2025 from $11.4 million in Q2 2024, furthering the company’s pre-commercial losses and pushing back its route to profitability. (Reuters)
Total GAAP costs and expenses jumped to $20.3 million in Q2 2025, up from $11.7 million a year ago, as administrative and R&D spending rose sharply, raising the risk of extended cash outflow. (Reuters)
Cash and cash equivalents fell from $119.3 million as of March 31, 2025, to $106.3 million at June 30, 2025, representing a $13 million quarter-over-quarter cash burn with no offsetting revenue. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
PLSE Financial Performance
Revenues and expenses
PLSE Earnings Performance
Company profitability
PLSE News
AllArticlesVideos
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
Business Wire3 weeks ago
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
Business Wire1 month ago
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pulse Biosciences stock?
Pulse Biosciences (PLSE) has a market cap of $977M as of September 14, 2025.
What is the P/E ratio for Pulse Biosciences stock?
The price to earnings (P/E) ratio for Pulse Biosciences (PLSE) stock is 0 as of September 14, 2025.
Does Pulse Biosciences stock pay dividends?
No, Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Pulse Biosciences dividend payment date?
Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulse Biosciences?
Pulse Biosciences (PLSE) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.